Melatonin agonists and insomnia

References

• Lerner AB, Case JD, Heinzelman RW. Structure of melatonin. J. Am. Chem. Soc.81, 6084–6085 (1959).
   Web of Science ®Google Scholar
• Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron13(5), 1177–1185 (1994).
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Golombek DA. Let there be sleep – on time. Lancet373, 438–440 (2009).
   PubMed Web of Science ®Google Scholar
• Rusak B. The mammalian circadian system: models and physiology. J. Biol. Rhythms4(2), 121–134 (1989).
   PubMed Web of Science ®Google Scholar
• Inouye S-I, Kawamura H. Persistence of circadian rhythmicity in a mammalian hypothalamic “island” containing the suprachiasmatic nucleus. Proc. Natl Acad. Sci. USA76(11), 5962–5966 (1979).
   PubMed Web of Science ®Google Scholar
• Maywood ES, O’Neill JS, Chesham JE, Hastings MH. The circadian clockwork of the suprachiasmatic nuclei – analysis of a cellular oscillator that drives endocrine rhythms. Endocrinology148(12), 5624–5634 (2007).
   PubMed Web of Science ®Google Scholar
• Young MY. Life’s 24-hour clock: molecular control of circadian rhythms in animal cells. Trends Biochem. Sci.25, 601–606 (2000).
   PubMed Web of Science ®Google Scholar
• Clayton JD, Kyriacou CP, Reppert SM. Keeping time with the human genome. Nature409, 829–831 (2001).
   PubMed Web of Science ®Google Scholar
• Sehgal A, Ousley A, Yang Z, Chen Y, Schotland P. What makes the circadian clock tick: Genes that keep time? Recent Prog. Horm. Res.54, 61–84 (1999).
   PubMedGoogle Scholar
• Wright KP, Hughes RJ, Kronauer RE, Dijk D, Czeisler CA. Intrinsic near-24-h pacemaker period determines limits of circadian entrainment to a weak synchronizer in humans. Proc. Natl Acad. Sci. USA98(24), 14027–14032 (2001).
   PubMed Web of Science ®Google Scholar
• Arendt J. Melatonin. Clin. Endocrinol.29, 205–229 (1988).
   PubMed Web of Science ®Google Scholar
• Arendt J. Melatonin and the Mammlian Pineal Gland. Springer, Berlin, Germany (1996).
   Google Scholar
• Dawson D, Armstrong SM. Chronobiotics – drugs that shift rhythms. Pharmacol. Ther.69(1), 15–36 (1996).
   PubMed Web of Science ®Google Scholar
• Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med. Rev.9, 25–39 (2005).
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: a sleep-promoting hormone. Sleep20, 899–907 (1997).
   PubMed Web of Science ®Google Scholar
• Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci.17(3), 100–102 (1996).
   PubMed Web of Science ®Google Scholar
• Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med.8(Suppl. 3), 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Rajaratnam SMW, Polymeropolous MH, Fisher DM et al. Melatonin agonist tasimelteon (VEC-192) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet373(9662), 482–491 (2009).
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology48(2), 301–310 (2005).
   PubMed Web of Science ®Google Scholar
• McArthur AJ, Hunt AE, Gillette MU. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn. Endocrinology138(2), 627–634 (1997).
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Yun K, Alghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor anatagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J.12(12), 1211–1220 (1998).
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Hudson RL, Sumaya IC, Masan MI, Manna E. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the c57BL/6 mouse. J. Pineal Res.39(2), 113–120 (2005).
   PubMed Web of Science ®Google Scholar
• Redman JR. Circadian entrainment and phase shifting in mammals with melatonin. J. Biol. Rhythms12(6), 581–587 (1997).
   PubMed Web of Science ®Google Scholar
• Rajaratnam SMW, Cohen DA, Rogers NL. Melatonin and melatonin analogues. Sleep Med. Clin.4(2), 179–193 (2009).
   Google Scholar
• Zee P, Manthena P. The brain’s master circadian clock: Implications and opportunities for therapy of sleep disorders. Sleep Med. Rev.11, 59–70 (2007).
   PubMed Web of Science ®Google Scholar
• Arendt J, Middleton B, Stone B, Skene DJ. Complex effects of melatonin: Evidence for photoperiodic responses in humans? Sleep22(5), 625–635 (1999).
   PubMed Web of Science ®Google Scholar
• Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. J. Physiol.586(2), 639–647 (2008).
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Bauer VK, Ahmed S et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol. Int.15(1), 71–83 (1998).
   PubMed Web of Science ®Google Scholar
• Sack RL, Lewy AJ, Hoban TM. Free-running melatonin rhythms in blind people: phase shifts with melatonin and triazolam administration. In: Temporal Disorder in Human Oscillatory Systems. Rensing, L, an der Heiden, U, Mackey, MC (Eds). Springer-Verlag, Heidelberg, Germany 219–224 (1987).
   Google Scholar
• Deacon S, English J, Arendt J. Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans. Neurosci. Lett.178, 32–34 (1994).
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol.272(4 Pt 2), R1178–R1188 (1997).
   PubMed Web of Science ®Google Scholar
• Rajaratnam SMW, Dijk D, Middleton B, Stone BM, Arendt J. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion ot the 24-hour production of reproductive hormones. J. Clin. Endocrinol. Metabol.88(9), 4303–4309 (2003).
   PubMed Web of Science ®Google Scholar
• Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann. Clin. Biochem.43(Pt 5), 344–353 (2006).
   PubMed Web of Science ®Google Scholar
• Redman JR, Armstrong SM. Reentrainmnet of rat circadian activity rhythms: effects of melatonin. J. Pineal Res.5(2), 203–215 (1998).
   Google Scholar
• Hirai K, Kita M, Ohta H et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J. Biol. Rhythms20(1), 27–37 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J. Clin. Sleep Med.4(5), 456–461 (2008).
   PubMed Web of Science ®Google Scholar
• Vachharajani NN, Yeleswaram K, Boutlon DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J. Pharm. Sci.92(4), 760–772 (2003).
   PubMed Web of Science ®Google Scholar
• Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol. Biochem. Behav.54(4), 713–718 (1996).
   PubMed Web of Science ®Google Scholar
• Pitrosky B, Kirsch R, Malan A, Mocaer E, Pevet P. Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am. J. Physiol.277(3 Pt 2), R812–R828 (1999).
   PubMed Web of Science ®Google Scholar
• Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol. Biochem. Behav.46(1), 45–49 (1993).
   PubMed Web of Science ®Google Scholar
• Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology118(4), 358–390 (1995).
   Google Scholar
• Leproult R, Van Onderbergen A, L’Hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol.63, 298–304 (2005).
   PubMed Web of Science ®Google Scholar
• Arendt J. Importance and relevance of melatonin to human biological rhythms. J. Neuroendocrinol.15(4), 427–431 (2003).
   PubMed Web of Science ®Google Scholar
• Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med. Rev.9(1), 51–65 (2005).
   PubMed Web of Science ®Google Scholar
• Scheer FA, Zeitzer JM, Ayas NT, R. B, Czeisler CA, Shea JA. Reduced sleep efficiency in cervical spinal cord injury: association with abolished night time melatonin secretion. Spinal Cord44(2), 78–81 (2006).
   PubMed Web of Science ®Google Scholar
• Shibata S, Cassone VM, Moore RY. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci. Lett.97(1–2), 140–144 (1989).
   PubMed Web of Science ®Google Scholar
• Van Someren EJ. Sleep propensity of modulated by circadian and behavior-induced changes in cutaneous temperature. J. Therm. Biol.29, 437–444 (2004).
   Web of Science ®Google Scholar
• van den Heuvel C, Noone J, Lushington K, Dawson D. Changes in sleepiness and body temperature precede nocturnal sleep onset: evidence from a polysomnography study in young men. J. Sleep Res.7, 159–166 (1998).
   PubMed Web of Science ®Google Scholar
• Gilbert S, van den Heuvel C, Ferguson S, Dawson D. Thermoregulation as a sleep signalling system. Sleep Med. Rev.8(2), 81–93 (2003).
   Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Werth E, Wirz-Justice A. Warm feet promote the rapid onset of sleep. Nature401(6748), 36–37 (1999).
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Werth E, Wirz-Justice A. Functional link between distal vasodilation and sleep-onset latency? Am. J. Physiol. Regul. Integr. Comp. Physiol.278(3), R741–R748 (2000).
   PubMed Web of Science ®Google Scholar
• van den Heuvel C, Kennaway D, Dawson D. Thermoregulatory and soporific effects of very low dose melatonin injection. Am. J. Physiol.276, E249–E254 (1999).
   PubMedGoogle Scholar
• Gilbert S, van den Heuvel C, Dawson D. Daytime melatonin and tempazepam in young adult humans: equivalent effects on sleep latency and body temperature. J. Physiol.514(3), 905–914 (1999).
   PubMed Web of Science ®Google Scholar
• Van Someren EJ. More than a marker: interaction between the circadian regulation of temperature and sleep, age-related changes, and treatment possibilities. Chronobiol. Int.17(3), 313–354 (2000).
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Trahkt I et al. Melatonin and melatonergic drugs on sleep: Possible mechanisms of action. Int. J. Neurosci.119(6), 821–846 (2009).
   PubMed Web of Science ®Google Scholar
• van den Heuvel CJ, Ferguson SA, Macchi MM, Dawson D. Melatonin as a hypnotic: Con. Sleep Med. Rev.9, 71–80 (2004).
   Web of Science ®Google Scholar
• Bjorvatn B, Pallesen S. A practical approach to circadian rhythm sleep disorders. Sleep Med. Rev.13, 47–60 (2009).
   PubMed Web of Science ®Google Scholar
• Arendt J, Rajaratnam SMW. Melatonin and its agonists: an update. Br. J. Psychiatry193, 267–269 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbert S, van den Heuvel C, Kennaway D, Dawson D. Peripheral heat loss: a predictor of the hypothermic response to melatonin administration in young and older women. Physiol. Behav.66(2), 365–370 (1999).
   PubMed Web of Science ®Google Scholar
• Dawson D, Rogers N, van den Heuvel CJ, Kennaway DJ, Lushington K. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J. Biol. Rhythms13(6), 532–538 (1998).
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet346(8974), 541–544 (1995).
   PubMed Web of Science ®Google Scholar
• Otmani S, Demazieres A, Staner C et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol.23(8), 693–705 (2008).
   PubMed Web of Science ®Google Scholar
• Strogatz SH, Kronauer RE, Czeisler CA. Circadian pacemaker interferes with sleep onset at specific times each day: role in insomnia. Am. J. Physiol.252(1 Pt 2), R172–R178 (1987).
   Google Scholar
• Lavie P. Ultrashort sleep-waking schedule. III. ‘Gates’ and ‘forbidden zones’ for sleep. Electroencephalogr. Clin. Neurophysiol.63, 414–425 (1986).
   PubMedGoogle Scholar
• Rajaratnam SMW, Middleton B, Stone BM, Arendt J, Dijk D. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunties in humans. J. Physiol.561(Pt 1), 339–351 (2004).
   PubMed Web of Science ®Google Scholar
• Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA. Sleep-faciltating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep29(5), 609–618 (2006).
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer B, Hooton N et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restricton: a meta-analysis. Br. Med. J.332(7538), 385–393 (2006).
   PubMed Web of Science ®Google Scholar
• Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag (Cochrane Review). Cochrance Database Syst. Rev.2, CD001520 (2002).
   PubMedGoogle Scholar
• Buscemi N, Vandermeer B, Hooton N et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. J. Gen. Int. Med.20(12), 1151–1158 (2005).
   PubMed Web of Science ®Google Scholar
• Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med.5, 523–532 (2004).
   PubMed Web of Science ®Google Scholar
• van den Heuvel CJ, Reid KJ, Dawson D. Effect of atenolol on nocturnal sleep and temperature in young men: reversal by pharmacological doses of melatonin. Physiol. Behav.61(6), 795–802 (1997).
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep27(7), 1319–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res.1027(1–2), 59–66 (2004).
   PubMed Web of Science ®Google Scholar
• Descamps A, Rousset C, Millan MJ, Spedding M, Delagrange P, Cespuglio R. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture. Psychopharmacology205(1), 93–106 (2009).
   PubMed Web of Science ®Google Scholar
• Roth T, Stubbs C, Wash JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep28(3), 303–307 (2005).
   PubMed Web of Science ®Google Scholar
• Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med.10, 55–59 (2009).
   PubMed Web of Science ®Google Scholar
• Winkelman J, Kotagal S, Olson E, Scammel T, Schenck C, Spielman A (Eds). The International Classification of Sleep Disorders: Diagnostic and Coding Manual (2nd Edition). American Academy of Sleep Medicine, IL, USA (2005).
   Google Scholar
• Sack RL, Lewy AJ, Blood ML, Stevenson J, Keith LD. Melatonin administration to blind people: phase advances and entrainment. J. Biol. Rhythms6(3), 249–261 (1991).
   PubMed Web of Science ®Google Scholar
• Folkard S, Arendt J, Aldhous M, Kennett H. Melatonin stabilises sleep onset time in a blind man without entrainment of cortisol or temperature rhythms. Neurosci. Lett.113(2), 193–198 (1990).
   PubMed Web of Science ®Google Scholar
• Sharkey KM, Fogg LF, Eastman CI. Effects of melatonin administration on daytime sleep after simulated night shift work. J. Sleep Res.10(3), 181–192 (2001).
   PubMed Web of Science ®Google Scholar
• Dahlitz MJ, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep-phase syndrome: response to melatonin. Lancet337, 1121–1124 (1991).
   PubMed Web of Science ®Google Scholar
• Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J. Biol. Rhythms12(6), 604–617 (1997).
   PubMed Web of Science ®Google Scholar
• Nagtegall JE, Kerkhof GA, Smits MG, Swart AC, Van Der Meer YG. Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J. Sleep Res.7(2), 135–143 (1998).
   PubMed Web of Science ®Google Scholar
• Suhner A, Schlagenhauf P, Johnson R, Tschopp A, Steffen R. Comparitive study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol. Int.15(6), 655–666 (1998).
   PubMed Web of Science ®Google Scholar
• Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom. Med.63(1), 40–48 (2001).
   PubMed Web of Science ®Google Scholar
• Arendt J. Does melatonin improve sleep? Efficacy of melatonin. Br. Med. J.332(7540), 550 (2006).
   PubMedGoogle Scholar
• Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. Br. Med. J.292(6529), 1170 (1986).
   PubMed Web of Science ®Google Scholar
• Dagan Y, Yovel I, Hallis D, Eisenstein M, Raichik I. Evaluating the role of melatonin in the long-term treatment of delayed sleep phase syndrome (DSPS). Chronobiol. Int.15(2), 181–190 (1998).
   PubMed Web of Science ®Google Scholar
• Lockley SW, Skene DJ, James K, Thapan K, Wright J, Arendt J. Melatonin administration can entrain the free-running circadian system of blind subjects. J. Endocrinol.164(1), R1–R6 (2000).
   PubMed Web of Science ®Google Scholar
• Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N. Engl. J. Med.343(15), 1070–1077 (2000).
   PubMed Web of Science ®Google Scholar
• Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep18(7), 598–603 (1995).
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J. Clin. Endocrinol. Metabol.86(10), 4727–4730 (2001).
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Zhdanova IV. Improvement of sleep quality by melatonin. Lancet346(8988), 1491 (1995).
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadain phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep21(1), 52–68 (1998).
   PubMed Web of Science ®Google Scholar
• Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J. Sleep Res.4(1), 61–65 (1996).
   Google Scholar
• Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J. Sleep Res.16(4), 372–380 (2007).
   PubMed Web of Science ®Google Scholar
• Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med. Rev.12, 319–332 (2008).
   PubMed Web of Science ®Google Scholar
• Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med.7, 17–24 (2006).
   PubMed Web of Science ®Google Scholar
• Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med.7(4), 312–318 (2006).
   PubMed Web of Science ®Google Scholar
• Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr. Med. Res. Opin.23(5), 1005–1014 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh JK, Moscovitch A, Burke J, Farber R, Roth T. Efficacy and tolerability of indiplon in older adults with primary insomnia. Sleep Med.8(7–8), 753–759 (2007).
   PubMed Web of Science ®Google Scholar
• Scharf MB, Black J, Hull S, Landin R, Farber R. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep30(6), 743–752 (2007).
   PubMed Web of Science ®Google Scholar
• Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr. Dis. Treat.4(1), 69–79 (2008).
   PubMedGoogle Scholar
• Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry63(10), 1149–1157 (2006).
   PubMed Web of Science ®Google Scholar
• Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. Am. J. Psychiatry133(10), 1181–1186 (1976).
   PubMed Web of Science ®Google Scholar
• Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J. Psychiatry Neurosci.25(1), 48–52 (2000).
   PubMed Web of Science ®Google Scholar
• Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry155(8), 1119–1121 (1998).
   PubMed Web of Science ®Google Scholar
• Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci.29(2), 126–133 (2004).
   PubMed Web of Science ®Google Scholar
• Barden N, Shink E, Labbe M, Vacher R, Rochford F, Mocaer E. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatry29(6), 908–916 (2005).
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D’Haenen H. Determination of the dose of agoemlatine, a melatonergic agonist and selective 5HT-(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol.17(5), 239–247 (2002).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychpharmacol.16(2), 93–100 (2006).
   PubMed Web of Science ®Google Scholar
• Olie JP, Emsley R. Confirmed clinical efficacy of agomelatinin (25–50 mg) in major depression: two randomized, doubel-blind placebo controlled studies. Eur. Neuropsychpharmacol.15(Suppl. 3), S416 (2005).
   Google Scholar
• Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidperessant, agomelatine: Randomised, double-blind comparison with venlafaxine. J. Clin. Psychiatry, 68(11), 1723–1732 (2007).
   PubMed Web of Science ®Google Scholar
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry23, 396–402 (2008).
   PubMed Web of Science ®Google Scholar
• Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int. Clin. Psychopharmacol.21(Suppl. 1), S31–S35 (2006).
   PubMed Web of Science ®Google Scholar
• Kräuchi K, Cajochen C, Möri D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol.272(4 Pt 2), R1178–R1188 (1997).
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology28(4), 694–703 (2003).
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int. J. Neuropsychopharmacol.10(5), 691–696 (2007).
   PubMed Web of Science ®Google Scholar